Metformin IN Asthma for Overweight and Obese Individuals (MINA)
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This study tests metformin in adults who are overweight or have obesity. It is for people whose asthma is not well controlled despite using a regular asthma inhaler.
This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- Age 18 or older.
- Asthma diagnosed by a doctor and treated with regular asthma medicine.
- Asthma is not well controlled: an Asthma Control Test (ACT) score below 20, or at least one flare-up needing steroid medicine in the past 12 months.
- Body mass index (BMI), a measure of weight compared with height, of 25 or higher.
Who can't join
- Pregnant, breastfeeding, or planning to become pregnant in the next 6 months.
- Heart failure, or a heart attack or stroke in the past 6 months.
- Another long-term lung disease, such as COPD, damaged and widened airways, or diseases that cause lung scarring.
- Currently smoking, or past smoking totaling at least 20 pack-years—for example, one pack a day for 20 years.
- Long-term kidney disease with a kidney filtering test (eGFR) of 60 or less; or liver disease, including liver blood tests (AST or ALT) more than twice the upper normal limit.
- In a typical week, 8 or more alcoholic drinks for a woman or 15 or more for a man; or anemia (low hemoglobin), below 13 g/dL in men or 11 g/dL in women.
- Taking GLP-1 medicines for weight loss; or diabetes, shown by an A1C blood sugar test of 6.5% or higher or use of metformin or other diabetes medicines.
- Taking part in another clinical trial. Studies that only observe people are allowed.
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Inclusion Criteria: * Physician-diagnosed asthma on maintenance therapy * Not well-controlled asthma (ACT score \<20, or at least one asthma exacerbation requiring corticosteroids in the prior 12 months) * Overweight or obesity: Body mass index ≥25kg/m2 * Adult: Age ≥18 Exclusion Criteria: * Currently pregnant, expect to become pregnant in the next 6 months or are currently breastfeeding * Major cardiovascular disease: heart failure, heart attack or stroke within the last 6 months * Other chronic lung disease, inclusive of chronic obstructive pulmonary disease, bronchiectasis, interstitial lung disease, pulmonary fibrosis * Active smoking or former smoker with ≥20 pack-year smoking history * Chronic kidney disease: estimated glomerular filtration rate ≤60 mL/min/1.73 m2 * Heavy alcohol use: in a typical week, 8 or more drinks for a woman or 15 or more drinks for a man * Liver disease: elevation in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2x the upper limit of normal or prior diagnosis of liver disease * Anemia: hemoglobin \< 13 g/dl in males and hemoglobin \< 11 g/dl in females * Taking Glucagon Like Peptide 1(GLP-1) medications for weight loss * Diabetes (Hemoglobin A1C ≥ 6.5% or taking metformin or other medications used to treat diabetes) * Participation in any other clinical trial (observational studies are permitted)
Study sites (2)
MD
- Johns Hopkins University · Baltimore, MD 21224Rachelle Koehl · Study contact · 410-955-1530 · rkoehl1@jhmi.eduMeredith C McCormack, M.D., M.H.S. · Principal investigatorMore trials in Baltimore
TX
- Baylor College of Medicine · Houston, TX 77030Tianshi D Wu, M.D., M.H.S. · Study contactMore trials in Houston